{"id":70639,"date":"2023-10-09T17:06:33","date_gmt":"2023-10-09T17:06:33","guid":{"rendered":"https:\/\/www.imperialcrs.com\/blog\/?p=70639"},"modified":"2023-10-10T16:21:53","modified_gmt":"2023-10-10T16:21:53","slug":"the-future-of-clinical-trials-patient-engagement-and-technology","status":"publish","type":"post","link":"https:\/\/www.imperialcrs.com\/blog\/patient-recruitment-and-retention\/the-future-of-clinical-trials-patient-engagement-and-technology\/","title":{"rendered":"The Future of Clinical Trials, Patient Engagement, and Technology"},"content":{"rendered":"<p>Clinical trial recruitment and patient engagement practices have evolved and so has clinical trial technology.<\/p>\n<p><em>What does the future look like?<\/em><\/p>\n<p>I recently spoke with <a href=\"https:\/\/www.linkedin.com\/in\/matthewstumm\/\">Matthew Stumm<\/a>, founder and president of the Boston-based patient recruitment agency <a href=\"https:\/\/starkravinghealth.com\/\">Stark \/ Raving Health<\/a>.<\/p>\n<p>I\u2019ve known Matt for many years, and it\u2019s always fun to talk shop with him, because he has seen the long-term evolution of patient recruitment in the clinical trials space, from raw marketing-based patient recruitment to a much more robust and multi-faceted area of specialization.<\/p>\n<p>Plus, Matt is a Boston guy like me, so if we drop our Rs and use some local slang, we still understand each other.<\/p>\n<p>&nbsp;<\/p>\n<p><iframe loading=\"lazy\" title=\"Imperial Clinical Research Services - Executive Interview Series 4 at DIA 2023 Global Annual Meeting\" width=\"1170\" height=\"658\" src=\"https:\/\/www.youtube.com\/embed\/1QmHCTrJwIE?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" allowfullscreen><\/iframe><\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<h2><strong>It\u2019s No Longer About Making a Case for Patient Recruitment<\/strong><\/h2>\n<p>Matt highlighted what separates yesterday\u2019s trials from today\u2019s:<\/p>\n<p>\u201c<em>There has been a huge adoption shift from the past 1-15 years. <\/em><em>When I started out, it was a question of whether or not we would do patient recruitment, and now it\u2019s a question of how we are going to do patient recruitment.<\/em><\/p>\n<p><em>We have both seen a long-term evolution with regard to the issue of delayed enrollment of clinical trials. In the early 2000s, most projects were rescue situations. <\/em><\/p>\n<p><em>Today, large sponsors and CROs have specialized functions and teams focused on proactive approaches to driving enrollment and retention of study volunteers.&#8221;<\/em><\/p>\n<h2><strong>The Patient is a Partner<\/strong><\/h2>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-70672 alignright\" src=\"https:\/\/www.imperialcrs.com\/blog\/wp-content\/uploads\/2023\/10\/future-of-clinical-trials-patient-engagement-300x200.jpeg\" alt=\"\" width=\"421\" height=\"280\" srcset=\"https:\/\/www.imperialcrs.com\/blog\/wp-content\/uploads\/2023\/10\/future-of-clinical-trials-patient-engagement-300x200.jpeg 300w, https:\/\/www.imperialcrs.com\/blog\/wp-content\/uploads\/2023\/10\/future-of-clinical-trials-patient-engagement-1024x684.jpeg 1024w, https:\/\/www.imperialcrs.com\/blog\/wp-content\/uploads\/2023\/10\/future-of-clinical-trials-patient-engagement-768x513.jpeg 768w, https:\/\/www.imperialcrs.com\/blog\/wp-content\/uploads\/2023\/10\/future-of-clinical-trials-patient-engagement-780x516.jpeg 780w, https:\/\/www.imperialcrs.com\/blog\/wp-content\/uploads\/2023\/10\/future-of-clinical-trials-patient-engagement-585x391.jpeg 585w, https:\/\/www.imperialcrs.com\/blog\/wp-content\/uploads\/2023\/10\/future-of-clinical-trials-patient-engagement-263x175.jpeg 263w, https:\/\/www.imperialcrs.com\/blog\/wp-content\/uploads\/2023\/10\/future-of-clinical-trials-patient-engagement.jpeg 1080w\" sizes=\"auto, (max-width: 421px) 100vw, 421px\" \/><\/p>\n<p>Another observation we made is the growth in the importance of recognizing patients as critical study partners \u2013 and most importantly \u2013 the increase in buy-in that we are getting in the design and execution of clinical trials.<\/p>\n<p>This is a significant sea change from 20 years ago.<\/p>\n<p><em>\u201cI think the biggest thing I\u2019ve seen in the past five to seven years, in the post-marketing part of advertising for the actual approved drug, you\u2019re seeing an acknowledgment of the people who participated in the trial being included in the advertising, which to me is amazing, and was never done before,\u201d\u00a0 <\/em>Matt said.<\/p>\n<p><em>\u201cThat\u2019s a product of the big push that\u2019s happening here and within our world of patient recruitment of really making patients the center of the reason why clinical research is successful. Not only because of the researchers and the scientists and the sponsors\u2026 but without their participation, a lot of this just wouldn\u2019t be happening.\u201d<\/em><\/p>\n<p>And while it is good to see this post-trial recognition, I mentioned the importance of thanking participants while they are in the trial.<\/p>\n<p><a href=\"https:\/\/www.imperialcrs.com\/blog\/2023\/08\/28\/with-thanks-and-appreciation-strategies-for-retention-in-clinical-trials\/\">Appreciation<\/a> is a valid retention tool. It might come as a surprise, but this appreciation doesn\u2019t happen often enough.<\/p>\n<h2><strong>Clinical Trial Technology<\/strong><\/h2>\n<p>The clinical trials industry has always used technology, sometimes with hesitancy, but the industry has matured and changes are accelerating.<\/p>\n<p>\u201c<em>I see the appetite for that being much stronger, to try new things,\u201d\u00a0 <\/em>Matt said.<\/p>\n<p>The widespread adoption of the internet, global smartphone usage, bandwidth improvements, and general acceptance of these technologies in daily life have proved invaluable in raising awareness about clinical trials.<\/p>\n<p>Social media, paid search, and other forms of pay-per-click advertisement channels have allowed the industry to filter and direct messaging about clinical trials to individuals with a higher likelihood of matching the trial target criteria.<\/p>\n<p>This means more meaningful content for the end user, more effective channeling of referrals, and faster enrollment. It has also come with metrics that tell a story right through to prescreening and sometimes beyond, right into randomization.<\/p>\n<p>As such, campaigns are more effective and dollars can be shifted along the way to always ensure that return on investment is optimized.<\/p>\n<h1><strong>Artificial Intelligence: A Seismic Shift in Clinical Trial Technology<\/strong><\/h1>\n<p>Today, almost every discussion about technology includes artificial intelligence, and Matt said it cannot be overlooked.<\/p>\n<p>\u201c<em>We\u2019re at the very early stages of it, but I think it may come as a surprise to a lot of people in patient recruitment that artificial intelligence has been used in advertising and marketing for patient outreach for a number of years, just at a different scale,<\/em>\u201d Matt said.<\/p>\n<p>\u201c<em>I think we\u2019re at the cusp of really starting to break through,\u201d he said. \u201cThere\u2019s going to be a seismic shift in the next five years, just considering the adoption rate of how this industry takes on new technology. You\u2019ll be seeing real-time bidding, you\u2019ll see predictive analytics through advertising; I think there\u2019s a lot of exciting things coming down the pipeline<\/em>.\u201d<\/p>\n<p>But with artificial intelligence comes warnings.<\/p>\n<p>\u201c<em>My view, I think we have to have a lot of caution and a lot of oversight in what we\u2019re doing to make sure that we\u2019re protecting privacy, transparency, in how we\u2019re collecting data,<\/em>\u201d Matt said.<\/p>\n<p>I agree. Technology is a force, and our industry must never lose sight of putting the patient first.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Clinical trial recruitment and patient engagement practices have evolved and so has clinical trial technology. What does the future look like? I recently spoke with Matthew Stumm, founder and president of the Boston-based patient recruitment agency Stark \/ Raving Health. I\u2019ve known Matt for many&hellip;<\/p>\n","protected":false},"author":7,"featured_media":70673,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[379,35],"tags":[419,422,208,412,414,421,413,415,417,418,416,423,420],"class_list":["post-70639","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-patient-engagement","category-patient-recruitment-and-retention","tag-appreciation-in-clinical-trials","tag-artificial-intelligence-in-patient-outreach","tag-clinical-trial-recruitment","tag-clinical-trial-technology","tag-future-of-clinical-trials","tag-internet-and-clinical-trial-awareness","tag-patient-engagement-practices","tag-patient-recruitment-evolution","tag-patient-centered-clinical-research","tag-post-trial-recognition","tag-proactive-enrollment-approaches","tag-seismic-shift-in-technology","tag-technology-in-clinical-trials"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>The Future of Clinical Trials, Patient Engagement, and Technology - Imperial Clinical Research Services Blog<\/title>\n<meta name=\"description\" content=\"Clinical trial recruitment and patient engagement have evolved and so has clinical trial technology. What does the future look like?\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.imperialcrs.com\/blog\/patient-recruitment-and-retention\/the-future-of-clinical-trials-patient-engagement-and-technology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Future of Clinical Trials, Patient Engagement, and Technology - Imperial Clinical Research Services Blog\" \/>\n<meta property=\"og:description\" content=\"Clinical trial recruitment and patient engagement have evolved and so has clinical trial technology. What does the future look like?\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.imperialcrs.com\/blog\/patient-recruitment-and-retention\/the-future-of-clinical-trials-patient-engagement-and-technology\/\" \/>\n<meta property=\"og:site_name\" content=\"Imperial Clinical Research Services Blog\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-09T17:06:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-10-10T16:21:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.imperialcrs.com\/blog\/wp-content\/uploads\/2023\/10\/future-of-clinical-trials.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"658\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Dan McDonald\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dan McDonald\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/patient-recruitment-and-retention\\\/the-future-of-clinical-trials-patient-engagement-and-technology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/patient-recruitment-and-retention\\\/the-future-of-clinical-trials-patient-engagement-and-technology\\\/\"},\"author\":{\"name\":\"Dan McDonald\",\"@id\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/#\\\/schema\\\/person\\\/b51d07a38b5a99e1182dd1918173a2da\"},\"headline\":\"The Future of Clinical Trials, Patient Engagement, and Technology\",\"datePublished\":\"2023-10-09T17:06:33+00:00\",\"dateModified\":\"2023-10-10T16:21:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/patient-recruitment-and-retention\\\/the-future-of-clinical-trials-patient-engagement-and-technology\\\/\"},\"wordCount\":818,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/patient-recruitment-and-retention\\\/the-future-of-clinical-trials-patient-engagement-and-technology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/future-of-clinical-trials.jpeg\",\"keywords\":[\"Appreciation in Clinical Trials\",\"Artificial Intelligence in Patient Outreach\",\"Clinical Trial Recruitment\",\"clinical trial technology\",\"Future of Clinical Trials\",\"Internet and Clinical Trial Awareness\",\"Patient Engagement Practices\",\"Patient Recruitment Evolution\",\"Patient-Centered Clinical Research\",\"Post-Trial Recognition\",\"Proactive Enrollment Approaches\",\"Seismic Shift in Technology\",\"Technology in Clinical Trials\"],\"articleSection\":[\"Patient Engagement\",\"Patient Recruitment and Retention\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/patient-recruitment-and-retention\\\/the-future-of-clinical-trials-patient-engagement-and-technology\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/patient-recruitment-and-retention\\\/the-future-of-clinical-trials-patient-engagement-and-technology\\\/\",\"url\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/patient-recruitment-and-retention\\\/the-future-of-clinical-trials-patient-engagement-and-technology\\\/\",\"name\":\"The Future of Clinical Trials, Patient Engagement, and Technology - Imperial Clinical Research Services Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/patient-recruitment-and-retention\\\/the-future-of-clinical-trials-patient-engagement-and-technology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/patient-recruitment-and-retention\\\/the-future-of-clinical-trials-patient-engagement-and-technology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/future-of-clinical-trials.jpeg\",\"datePublished\":\"2023-10-09T17:06:33+00:00\",\"dateModified\":\"2023-10-10T16:21:53+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/#\\\/schema\\\/person\\\/b51d07a38b5a99e1182dd1918173a2da\"},\"description\":\"Clinical trial recruitment and patient engagement have evolved and so has clinical trial technology. What does the future look like?\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/patient-recruitment-and-retention\\\/the-future-of-clinical-trials-patient-engagement-and-technology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/patient-recruitment-and-retention\\\/the-future-of-clinical-trials-patient-engagement-and-technology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/patient-recruitment-and-retention\\\/the-future-of-clinical-trials-patient-engagement-and-technology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/future-of-clinical-trials.jpeg\",\"contentUrl\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/future-of-clinical-trials.jpeg\",\"width\":1080,\"height\":658,\"caption\":\"Future of clinical trials graphic\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/patient-recruitment-and-retention\\\/the-future-of-clinical-trials-patient-engagement-and-technology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The Future of Clinical Trials, Patient Engagement, and Technology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/\",\"name\":\"Imperial Clinical Research Services Blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/#\\\/schema\\\/person\\\/b51d07a38b5a99e1182dd1918173a2da\",\"name\":\"Dan McDonald\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/eadd7098b6c648f3acace4396c5f20b27a640b101214df774c63a5078311f706?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/eadd7098b6c648f3acace4396c5f20b27a640b101214df774c63a5078311f706?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/eadd7098b6c648f3acace4396c5f20b27a640b101214df774c63a5078311f706?s=96&d=mm&r=g\",\"caption\":\"Dan McDonald\"},\"description\":\"Dan is vice president, business development, Imperial Clinical Research Services. Dan is a seasoned executive who specializes in identifying income opportunities, building strategic partnerships, and managing contract negotiations. A prolific and popular thought leader, Dan has presented at numerous industry conferences and events, has conducted workshops and sessions on patient engagement, and has been published numerous times in industry books, trade magazines, and journals.\",\"url\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/author\\\/dmcdonald\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The Future of Clinical Trials, Patient Engagement, and Technology - Imperial Clinical Research Services Blog","description":"Clinical trial recruitment and patient engagement have evolved and so has clinical trial technology. What does the future look like?","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.imperialcrs.com\/blog\/patient-recruitment-and-retention\/the-future-of-clinical-trials-patient-engagement-and-technology\/","og_locale":"en_US","og_type":"article","og_title":"The Future of Clinical Trials, Patient Engagement, and Technology - Imperial Clinical Research Services Blog","og_description":"Clinical trial recruitment and patient engagement have evolved and so has clinical trial technology. What does the future look like?","og_url":"https:\/\/www.imperialcrs.com\/blog\/patient-recruitment-and-retention\/the-future-of-clinical-trials-patient-engagement-and-technology\/","og_site_name":"Imperial Clinical Research Services Blog","article_published_time":"2023-10-09T17:06:33+00:00","article_modified_time":"2023-10-10T16:21:53+00:00","og_image":[{"width":1080,"height":658,"url":"https:\/\/www.imperialcrs.com\/blog\/wp-content\/uploads\/2023\/10\/future-of-clinical-trials.jpeg","type":"image\/jpeg"}],"author":"Dan McDonald","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Dan McDonald","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.imperialcrs.com\/blog\/patient-recruitment-and-retention\/the-future-of-clinical-trials-patient-engagement-and-technology\/#article","isPartOf":{"@id":"https:\/\/www.imperialcrs.com\/blog\/patient-recruitment-and-retention\/the-future-of-clinical-trials-patient-engagement-and-technology\/"},"author":{"name":"Dan McDonald","@id":"https:\/\/www.imperialcrs.com\/blog\/#\/schema\/person\/b51d07a38b5a99e1182dd1918173a2da"},"headline":"The Future of Clinical Trials, Patient Engagement, and Technology","datePublished":"2023-10-09T17:06:33+00:00","dateModified":"2023-10-10T16:21:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.imperialcrs.com\/blog\/patient-recruitment-and-retention\/the-future-of-clinical-trials-patient-engagement-and-technology\/"},"wordCount":818,"commentCount":0,"image":{"@id":"https:\/\/www.imperialcrs.com\/blog\/patient-recruitment-and-retention\/the-future-of-clinical-trials-patient-engagement-and-technology\/#primaryimage"},"thumbnailUrl":"https:\/\/www.imperialcrs.com\/blog\/wp-content\/uploads\/2023\/10\/future-of-clinical-trials.jpeg","keywords":["Appreciation in Clinical Trials","Artificial Intelligence in Patient Outreach","Clinical Trial Recruitment","clinical trial technology","Future of Clinical Trials","Internet and Clinical Trial Awareness","Patient Engagement Practices","Patient Recruitment Evolution","Patient-Centered Clinical Research","Post-Trial Recognition","Proactive Enrollment Approaches","Seismic Shift in Technology","Technology in Clinical Trials"],"articleSection":["Patient Engagement","Patient Recruitment and Retention"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.imperialcrs.com\/blog\/patient-recruitment-and-retention\/the-future-of-clinical-trials-patient-engagement-and-technology\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.imperialcrs.com\/blog\/patient-recruitment-and-retention\/the-future-of-clinical-trials-patient-engagement-and-technology\/","url":"https:\/\/www.imperialcrs.com\/blog\/patient-recruitment-and-retention\/the-future-of-clinical-trials-patient-engagement-and-technology\/","name":"The Future of Clinical Trials, Patient Engagement, and Technology - Imperial Clinical Research Services Blog","isPartOf":{"@id":"https:\/\/www.imperialcrs.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.imperialcrs.com\/blog\/patient-recruitment-and-retention\/the-future-of-clinical-trials-patient-engagement-and-technology\/#primaryimage"},"image":{"@id":"https:\/\/www.imperialcrs.com\/blog\/patient-recruitment-and-retention\/the-future-of-clinical-trials-patient-engagement-and-technology\/#primaryimage"},"thumbnailUrl":"https:\/\/www.imperialcrs.com\/blog\/wp-content\/uploads\/2023\/10\/future-of-clinical-trials.jpeg","datePublished":"2023-10-09T17:06:33+00:00","dateModified":"2023-10-10T16:21:53+00:00","author":{"@id":"https:\/\/www.imperialcrs.com\/blog\/#\/schema\/person\/b51d07a38b5a99e1182dd1918173a2da"},"description":"Clinical trial recruitment and patient engagement have evolved and so has clinical trial technology. What does the future look like?","breadcrumb":{"@id":"https:\/\/www.imperialcrs.com\/blog\/patient-recruitment-and-retention\/the-future-of-clinical-trials-patient-engagement-and-technology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.imperialcrs.com\/blog\/patient-recruitment-and-retention\/the-future-of-clinical-trials-patient-engagement-and-technology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.imperialcrs.com\/blog\/patient-recruitment-and-retention\/the-future-of-clinical-trials-patient-engagement-and-technology\/#primaryimage","url":"https:\/\/www.imperialcrs.com\/blog\/wp-content\/uploads\/2023\/10\/future-of-clinical-trials.jpeg","contentUrl":"https:\/\/www.imperialcrs.com\/blog\/wp-content\/uploads\/2023\/10\/future-of-clinical-trials.jpeg","width":1080,"height":658,"caption":"Future of clinical trials graphic"},{"@type":"BreadcrumbList","@id":"https:\/\/www.imperialcrs.com\/blog\/patient-recruitment-and-retention\/the-future-of-clinical-trials-patient-engagement-and-technology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.imperialcrs.com\/blog\/"},{"@type":"ListItem","position":2,"name":"The Future of Clinical Trials, Patient Engagement, and Technology"}]},{"@type":"WebSite","@id":"https:\/\/www.imperialcrs.com\/blog\/#website","url":"https:\/\/www.imperialcrs.com\/blog\/","name":"Imperial Clinical Research Services Blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.imperialcrs.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.imperialcrs.com\/blog\/#\/schema\/person\/b51d07a38b5a99e1182dd1918173a2da","name":"Dan McDonald","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/eadd7098b6c648f3acace4396c5f20b27a640b101214df774c63a5078311f706?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/eadd7098b6c648f3acace4396c5f20b27a640b101214df774c63a5078311f706?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/eadd7098b6c648f3acace4396c5f20b27a640b101214df774c63a5078311f706?s=96&d=mm&r=g","caption":"Dan McDonald"},"description":"Dan is vice president, business development, Imperial Clinical Research Services. Dan is a seasoned executive who specializes in identifying income opportunities, building strategic partnerships, and managing contract negotiations. A prolific and popular thought leader, Dan has presented at numerous industry conferences and events, has conducted workshops and sessions on patient engagement, and has been published numerous times in industry books, trade magazines, and journals.","url":"https:\/\/www.imperialcrs.com\/blog\/author\/dmcdonald\/"}]}},"_links":{"self":[{"href":"https:\/\/www.imperialcrs.com\/blog\/wp-json\/wp\/v2\/posts\/70639","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.imperialcrs.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.imperialcrs.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.imperialcrs.com\/blog\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.imperialcrs.com\/blog\/wp-json\/wp\/v2\/comments?post=70639"}],"version-history":[{"count":14,"href":"https:\/\/www.imperialcrs.com\/blog\/wp-json\/wp\/v2\/posts\/70639\/revisions"}],"predecessor-version":[{"id":70685,"href":"https:\/\/www.imperialcrs.com\/blog\/wp-json\/wp\/v2\/posts\/70639\/revisions\/70685"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.imperialcrs.com\/blog\/wp-json\/wp\/v2\/media\/70673"}],"wp:attachment":[{"href":"https:\/\/www.imperialcrs.com\/blog\/wp-json\/wp\/v2\/media?parent=70639"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.imperialcrs.com\/blog\/wp-json\/wp\/v2\/categories?post=70639"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.imperialcrs.com\/blog\/wp-json\/wp\/v2\/tags?post=70639"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}